Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7
|
作者：
Ecke, Thorsten H. [1 ]
机构：
[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany
来源：
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷
关键词：
Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
D O I：
10.1007/978-94-017-7215-0_18
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.
引用
收藏
页码：293 / 316
页数：24
相关论文
共 50 条
  • [31] Role of Systemic Chemotherapy in Urothelial Urinary Bladder Cancer
    Gupta, Shilpa
    Mahipal, Amit
    CANCER CONTROL, 2013, 20 (03) : 200 - 210
  • [32] Neoadjuvant Chemotherapy for Invasive Bladder Cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    CURRENT UROLOGY REPORTS, 2012, 13 (02) : 136 - 146
  • [33] Regarding the effect of cisplatin-based chemotherapy on hearing loss in children with cancer
    Xiang, Li
    Liu, Ye
    Liu, Jinlin
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2024, 45 (04)
  • [34] Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder
    Minato, Akinori
    Fujimoto, Naohiro
    Kubo, Tatsuhiko
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E1063 - E1067
  • [35] Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
    Plimack, Elizabeth R.
    Dunbrack, Roland L.
    Brennan, Timothy A.
    Andrake, Mark D.
    Zhou, Yan
    Serebriiskii, Ilya G.
    Slifker, Michael
    Alpaugh, Katherine
    Dulaimi, Essel
    Palma, Norma
    Hoffman-Censits, Jean
    Bilusic, Marijo
    Wong, Yu-Ning
    Kutikov, Alexander
    Viterbo, Rosalia
    Greenberg, Richard E.
    Chen, David Y. T.
    Lallas, Costas D.
    Trabulsi, Edouard J.
    Yelensky, Roman
    McConkey, David J.
    Miller, Vincent A.
    Golemis, Erica A.
    Ross, Eric A.
    EUROPEAN UROLOGY, 2015, 68 (06) : 959 - 967
  • [36] A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer
    Hussain, S. A.
    Palmer, D. H.
    Lloyd, B.
    Collins, S. I.
    Barton, D.
    Ansari, J.
    James, N. D.
    ONCOLOGY LETTERS, 2012, 3 (04) : 855 - 859
  • [37] Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer
    Osterman, Chelsea K.
    Babu, Dilip S.
    Geynisman, Daniel M.
    Lewis, Bianca
    Somer, Robert A.
    Balar, Arjun V.
    Zibelman, Matthew R.
    Guancial, Elizabeth A.
    Antinori, Gianna
    Yu, Shun
    Narayan, Vivek
    Guzzo, Thomas J.
    Plimack, Elizabeth R.
    Vaughn, David J.
    Fung, Chunkit
    Mamtani, Ronac
    ONCOLOGIST, 2019, 24 (05) : 688 - 690
  • [38] Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
    Apolo, Andrea B.
    Ostrovnaya, Irina
    Halabi, Susan
    Iasonos, Alexia
    Philips, George K.
    Rosenberg, Jonathan E.
    Riches, Jamie
    Small, Eric J.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (07): : 499 - 503
  • [39] Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma
    Bellmunt, J
    Ribas, A
    Eres, N
    Albanell, J
    Almanza, C
    Bermejo, B
    Sole, LA
    Baselga, J
    CANCER, 1997, 80 (10) : 1966 - 1972
  • [40] Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer
    Yen, MS
    Juang, CM
    Lai, CR
    Chao, GC
    Ng, HT
    Yuan, CC
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2001, 72 (01) : 55 - 60
12345